What do HTA decisionmakers care about?

Is it clinical benefit? Cost? Value? The availability of treatment alternatives? To answer this question, a paper by Wranik et al. (2019) conducted a discrete choice experiment DCE to determine HTA stakeholders stated preferences. The sample consisted of HTA stakeholders from 5 countries: Australia, Canada, Germany, Poland, and the United Kingdom. The stakeholders included not…

What is attribute non-attendance?

In discrete choice experiments (DCEs), respondents are asked to choose amoung different options which vary across different attributes. For instance, a DCE on mobile phone preferences could have processor speed, battery life, screen size and cost as attributes. A DCE looking at different treatments could have expected survival, anticipated side effects and cost as attributes.…